Cover Image
市場調查報告書

遺傳性血管水腫 (HAE) (C1酯酶抑制物缺損症) :全球臨床實驗趨勢

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 350882
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
遺傳性血管水腫 (HAE) (C1酯酶抑制物缺損症) :全球臨床實驗趨勢 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017
出版日期: 2017年09月15日 內容資訊: 英文 95 Pages
簡介

本報告提供遺傳性血管水腫 (HAE) (C1酯酶抑制物缺損症)相關之臨床研究最新趨勢分析,提供您疾病·治療方法概要,G7及E7各國的臨床實驗狀況,各地區、各階段的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,並彙整有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 主要國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 主要國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:遺傳性血管水腫 (HAE) (C1酯酶抑制物缺損症) 臨床實驗數量的免疫學臨床實驗數量比例

Phase別臨床實驗數量: G7各國

G7各國的臨床實驗數量:Phase別

E7各國的臨床實驗數量:遺傳性血管水腫 (HAE) (C1酯酶抑制物缺損症) 臨床實驗數量的免疫學臨床實驗數量比例

Phase別臨床實驗數量: E7各國

E7各國的臨床實驗數量:Phase別

Phase別臨床實驗數量

  • Phase別的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 遺傳性血管水腫 (HAE) (C1酯酶抑制物缺損症) 治療藥

有潛力的藥劑

  • 最新臨床實驗新聞:遺傳性血管水腫 (HAE) (C1酯酶抑制物缺損症)

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4577CTIDB

GlobalData's clinical trial report, "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017" provides an overview of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials 21
  • Clinical Trials by Phase in E7 Countries 23
  • Clinical Trials in E7 Countries by Trial Status 24
  • Clinical Trials by Phase 25
  • In Progress Trials by Phase 26
  • Clinical Trials by Trial Status 27
  • Clinical Trials by End Point Status 28
  • Subjects Recruited Over a Period of Time 29
  • Clinical Trials by Sponsor Type 30
  • Prominent Sponsors 31
  • Top Companies Participating in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials 33
  • Prominent Drugs 35
  • Latest Clinical Trials News on Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) 36
  • Sep 11, 2017: Pharming Announces Conclusion of FDA End of Phase 2 Interactions on RUCONEST for Prophylaxis of HAE 36
  • Sep 05, 2017: BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE 36
  • Aug 02, 2017: BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks 37
  • Jul 26, 2017: Pharming Announces Publication of RUCONEST Prophylactic Data in The Lancet 37
  • Clinical Trial Profile Snapshots 38

Appendix 93

  • Abbreviations 93
  • Definitions 93
  • Research Methodology 94
  • Secondary Research 94
  • About GlobalData 95
  • Contact Us 95
  • Source 95

List of Tables

List of Tables

  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 12
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 16
  • Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, G7 Countries (%), 2017* 18
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, E7 Countries (%), 2017* 22
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Phase, 2017* 25
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 28
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 29
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 30
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 35

List of Figures

List of Figures

  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 12
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 16
  • Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, G7 Countries (%), 2017* 17
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, E7 Countries (%), 2017* 21
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 28
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 29
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 30
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 35
  • GlobalData Methodology 94
Back to Top